UK / Pharma Industry Warns of Declining Competitiveness
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly's departure from the country's voluntary medicines pricing agreement, Moderna's expanded footprint, UK biotech's 2022 funding downturn and Gilead's Yescarta approval from NICE. Northern Ireland…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Life sciences have been steadily losing ground in the UK with a significant drop in global R&D investments and a decreasing number of patients enrolled in clinical trials. The British…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of his company. Unlike many of your peers, you are very optimistic about Brexit. What opportunities do you believe Brexit will create for Britain and the life sciences industry in the…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life…
The latest news from UK healthcare and the life sciences, including a record rise in the number of people using private healthcare services due to significant strains on the National…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
Igor Bondarenko of Ukraine’s Dnipro State Medical University, Evgeny Levenko from clinical trials company, ARENSIA, and Olena Popova from IQVIA offer their perspectives on maintaining quality and ensuring participant protection…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Anina Adelfio…
The March edition of DIA’s Global Forum magazine features a special section on clinical research in Ukraine, over one year on from the beginning of the Russian invasion. Here, Chieko…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
See our Cookie Privacy Policy Here